Particularly exciting are the potential applications of IDO inhibitors in lessening the negative neurocognitive effects of a number of common clinical scenarios ranging from delirium in the hospitalized patient to radiotherapy for CNS tumors to COVID-related cognitive impairment. This evidence concerns the gene IDO1 and delirium.